Healthcare · Enterprise · Emerging

Lack of detailed understanding of drug mechanisms and potential risks of AI in clinical trials

Pharmaceutical companies struggle to understand drug mechanisms in detail, and there are concerns about the safety and effectiveness of AI-run clinical trials.

Who experiences it: Pharmaceutical companies

Momentum

0%

Pain

75

Competition

90

Opportunity

60/100

Signals over time

3 observed signals across 1 sources, tracked for 2 days. Confidence: low.

What people are saying Observed

  • “>I ask nearly every doctor/researched in the medical field: if you had a AI-created drug that tremendously improved cancer treatment outcomes for your patient, would you hesitate to prescribe it because nobody understood how it worked? I have yet to hear "yes, I would hesitate", most people say "it would be cruel to deny a person a treatment that worked". You think that way because you're already working on an unfounded assumption, namely that the AI found a cure for cancer and that the drug has already went through clinical trials. What you don't consider is that e.g. a cancer researcher might have produced a million AI created drugs and one of them is a potent drug for cancer and 999999 other drugs are useless, actively harmful or even deadly. Now you go to to the same guy and say "You have an AI-created drug that tremendously improves cancer treatment outcomes. Why would you hesitate to prescribe it, because nobody understands how it works?" And suddenly you are injecting 999999 useless AI created treatments into people to find the one cure that works.”

    Hacker News · frustration

  • “> [...] would you hesitate to prescribe it because nobody understood how it worked? I have yet to hear "yes, I would hesitate", most people say "it would be cruel to deny a person a treatment that worked". I feel like the way you frame the question makes answering it very easy but oversimplifies the reality. In a situation where an AI suggests a treatment to you without explanation and it appears to work, probably you can't even determine that the improved outcome is due to the drug or due to randomness (yes there are really rare cases where people recovered from stage 4 cancer). Especially if it's a personalized drug. If in this hypothetical world "it works on the patients I've tried it on" is good enough to try the drug, and you're willing to potentially cause harm if it doesn't work, then what's the line between science and pseudoscience/quack medicine? Every treatment surely "appears to work" in at least some cases. So wouldn't it be cruel to deny the patient a try at every last treatment that has ever worked for someone in the past, including practices like bloodletting, acupuncture, etc? Would ”

    Hacker News · frustration

  • “I think the best thing to say is that by thinking through the example, sharing it with people in the field, and then steelmanning it, he might have had some good points: 1) pharma would love to understand the mechanisms of drugs in detail but we don't have that. AI could help. 2) there is a possibility that a clinical trial run by AI could hack the trial get something approved when it wasn't safe or effective.”

    Hacker News · complaint

Why now? AI inference

Existing solutions Observed

  • IBM Watson for Drug Discovery · Unknown · complaints: High cost of implementation, Complexity of use for non-technical staff, Limited access to certain datasets
  • TrialSpark · Unknown · complaints: Limited geographical reach for trials, Dependence on external sites for patient recruitment, Occasional technical glitches in the platform
  • BioSymetrics · Unknown · complaints: Steep learning curve for new users, Limited customization options, Occasional data integration issues
  • CureMetrix · Unknown · complaints: Requires extensive training for effective use, May not cover all therapeutic areas, Data privacy concerns raised by users
  • Medidata Solutions · Unknown · complaints: High cost for smaller companies, Complex interface can be overwhelming, Customer support response times can be slow

There is a significant gap in the market for a user-friendly, cost-effective solution that provides detailed insights into drug mechanisms and the potential risks of AI in clinical trials. Current competitors, such as IBM Watson for Drug Discovery and Medidata Solutions, face complaints regarding high costs and complexity, which may deter smaller pharmaceutical companies from leveraging AI effectively.

See the full evidence, competitor gap matrix and opportunity report.

Free account. No credit card.